Optalert Pushes Further into Medtech, Appointing Experienced Technology Commercialisation Specialist, Christine Cussen to its Board.

Tuesday, 14 September 2021

Optalert, the world’s leader in drowsiness and alertness detection, today appointed Non-executive Director Ms Christine Cussen to its board. 

Ms Cussen has a long and distinguished career with decades of executive and board experience across diverse industry sectors in listed, private and government sectors including global pharmaceutical, biotechnology, medical, industrial, and environmental. She is currently a business advisor for medical technologies and pharmaceuticals to the Australian Industry Group, a Non-Executive Director of Goulburn Valley Water and Chair of their Audit and Risk Committee.

“Christine has a uniquely entrepreneurial mindset and is deeply passionate about growing businesses, caring for customers, people and, ultimately, the health of the business,” said Chairman Brian Wilson. “We are delighted to welcome her to our board.”

“Christine’s commercial background and international business experience will serve us well as we continue to progress both our advanced driver monitoring technology and our research into neurological biomarker detection beyond drowsiness. “ added Scott Coles, CEO.

Ms Cussen’s appointment further cements Optalert’s dedication to innovation and business growth across varied sectors including mining, gas and oil, road transport, automotive, scientific research, pharmaceutical drug trials and neurological research. 

Ms Cussen brings highly sought-after governance, risk management and compliance skills and a proven track record in business growth, capital markets, international business development, licensing, and technology commercialisation.

“I strongly believe in Optalert’s story, its innovative technology, and its business practice and I am pleased to be able to play a part in its on-going development and future success,” says Ms Cussen.